Bone health in prostate cancer

References

• Lattouf JB, Saad F. Bone health in nonmetastatic prostate cancer: what’s the big deal? Curr. Oncol.17(Suppl. 2), S49–S54 (2010).
   PubMedGoogle Scholar
• Saad F, Eastham J. Maintaining bone health in prostate cancer throughout the disease continuum. Semin. Oncol.37(Suppl. 1), S30–S37 (2010).
   Google Scholar
• Saylor PJ, Smith MR. Bone health and prostate cancer. Prostate Cancer Prostatic Dis.13, 20–27 (2010).
   PubMed Web of Science ®Google Scholar
• Soloway MS. Efficacy of buserelin in advanced prostate cancer and comparison with historical controls. Am. J. Clin. Oncol.11(Suppl. 1), S29–S32 (1988).
   Google Scholar
• Lukkarinen O, Kontturi M. Comparison of a long-acting LHRH agonist and polyoestradiol phosphate in the treatment of advanced prostatic carcinoma. An open prospective, randomized multicentre study. Scand. J. Urol. Nephrol.28, 171–178 (1994).
   PubMed Web of Science ®Google Scholar
• Hamilton EJ, Ghasem-Zadeh A, Gianatti E et al. Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy. J. Clin. Endocrinol. Metab.95(12), E456–E463 (2010).
   Web of Science ®Google Scholar
• Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med.352, 154–164 (2005).
   PubMed Web of Science ®Google Scholar
• Serpa Neto A, Tobias-Machado M, Esteves MA et al. A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma. BMC Urol.10, 9 (2010).
   PubMedGoogle Scholar
• Alibhai SM, Duong-Hua M, Cheung AM et al. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J. Urol.184, 918–923 (2010).
   PubMed Web of Science ®Google Scholar
• Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer110, 1860–1867 (2007).
   PubMed Web of Science ®Google Scholar
• Spry NA, Galvao DA, Davies R et al. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study. BJU Int.104, 806–812 (2009).
   PubMed Web of Science ®Google Scholar
• Diamond TH, Winters J, Smith A et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer92, 1444–1450 (2001).
   PubMed Web of Science ®Google Scholar
• Michaelson MD, Kaufman DS, Lee H et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J. Clin. Oncol.25, 1038–1042 (2007).
   PubMed Web of Science ®Google Scholar
• Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J. Urol.176, 972–978, discussion 978 (2006).
   PubMed Web of Science ®Google Scholar
• Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J. Urol.169, 2008–2012 (2003).
   PubMed Web of Science ®Google Scholar
• Casey R, Gesztesi Z, Rochford J. Long term zoledronic acid during androgen blockade for prostate cancer. Can. J. Urol.17, 5170–5177 (2010).
   PubMedGoogle Scholar
• Schwarz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Res. Ther.99(Suppl. 1), S7 (2007).
   Google Scholar
• Fizazi K, Bosserman L, Gao G, Skacel T, Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized Phase II trial. J. Urol.182, 509–515, discussion 515–516 (2009).
   PubMed Web of Science ®Google Scholar
• Smith MR, Egerdie B, Hernandez Toriz N et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med.361, 745–755 (2009).
   PubMed Web of Science ®Google Scholar
• Szmulewitz R, Mohile S, Posadas E et al. A randomized Phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur. Urol.56, 97–103 (2009).
   PubMedGoogle Scholar
• Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann. Intern. Med.146, 416–424 (2007).
   PubMed Web of Science ®Google Scholar
• Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N. Engl. J. Med.345, 948–955 (2001).
   PubMed Web of Science ®Google Scholar
• Saad F, Abrahamsson PA, Miller K. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates. BJU Int.104, 1573–1579 (2009).
   PubMedGoogle Scholar
• Planas J, Trilla E, Raventos C et al. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. BJU Int.104, 1637–1640 (2009).
   PubMedGoogle Scholar
• Greenspan SL, Nelson JB, Trump DL et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J. Clin. Oncol.26, 4426–4434 (2008).
   PubMed Web of Science ®Google Scholar
• Berry S, Waldron T, Winquist E, Lukka H. The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials. Can. J. Urol.13, 3180–3188 (2006).
   PubMedGoogle Scholar
• Saad F. New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat. Rev.34, 183–192 (2008).
   PubMed Web of Science ®Google Scholar
• Lipton A, Cook R, Saad F et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer113, 193–201 (2008).
   PubMed Web of Science ®Google Scholar
• Saad F, Lipton A. Bone-marker levels in patients with prostate cancer: potential correlations with outcomes. Curr. Opin. Support Palliat. Care4, 127–134 (2010).
   PubMedGoogle Scholar
• Smith MR, Saad F, Egerdie B et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J. Urol.182, 2670–2675 (2009).
   PubMed Web of Science ®Google Scholar
• Smith MR, Morton RA, Barnette KG et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer, J. Urol.184, 1316–1321 (2010).
   PubMed Web of Science ®Google Scholar
• Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J. Clin. Endocrinol. Metab.89, 3841–3846 (2004).
   PubMed Web of Science ®Google Scholar
• Saad F. Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int.103, 434–440 (2009).
   PubMed Web of Science ®Google Scholar
• Araujo JC, Poblenz A, Corn P et al. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation. Cancer Biol. Ther.8, 2153–2159 (2009).
   PubMed Web of Science ®Google Scholar
• Yang JC, Bai L, Yap S, Gao AC, Kung HJ, Evans CP. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model. Mol. Cancer Ther.9, 1629–1637 (2010).
   PubMed Web of Science ®Google Scholar
• Vandyke K, Dewar AL, Diamond P et al. The tyrosine kinase inhibitor dasatinib dysregulates bone remodelling through inhibition of osteoclasts in vivo. J. Bone Miner. Res.25(8), 1759–1770 (2010).
   PubMed Web of Science ®Google Scholar
• Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J. Clin. Oncol.28, 340–347 (2010).
   PubMed Web of Science ®Google Scholar
• Newton RU, Taaffe DR, Spry N et al. A Phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancer. BMC Cancer9, 210 (2009).
   PubMed Web of Science ®Google Scholar
• Mulders PF, Abrahamsson PA, Bukowski RM. Burden of metastatic bone disease from genitourinary malignancies. Expert Rev. Anticancer Ther.10, 1721–1733 (2010).
   PubMed Web of Science ®Google Scholar
• Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst. Rev.CD006250 (2006).
   Google Scholar
• Velde NV, Wu EQ, Guo A et al. The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population. Prostate Cancer Prostatic Dis.14(1), 79–84 (2010).
   PubMedGoogle Scholar
• Nelson DM, Peterson AC. Changes in bone health and skeletal-related events following implementation of a multidisciplinary consensus statement guiding surveillance and treatment of men undergoing androgen deprivation therapy for prostate cancer. Aging Male13, 120–123 (2010).
   PubMed Web of Science ®Google Scholar
• Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomized controlled trials. Lancet Oncol.10, 872–876 (2009).
   PubMed Web of Science ®Google Scholar
• Fizazi K, Lipton A, Mariette X et al. Randomized Phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J. Clin. Oncol.27, 1564–1571 (2009).
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci MA, Smith MR et al. A randomized Phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. 2010 ASCO Annual Meeting Proceedings (post-meeting edition). J. Clin. Oncol. 28, 18(Suppl.), LBA4507 (2010).
   Google Scholar
• Brown JE, Sim S. Evolving role of bone biomarkers in castration-resistant prostate cancer. Neoplasia12, 685–696 (2010).
   PubMedGoogle Scholar
• Alibhai SM, Duong-Hua M, Sutradhar R et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J. Clin. Oncol.27, 3452–3458 (2009).
   PubMed Web of Science ®Google Scholar